REVIEW
FSDA-DG: Improving Cross-Domain Generalizability of Medical Image Segmentation with Few Source Domain Annotations
Not yet reviewed by Pith; the record is open.
This paper has not been read by Pith yet. Machine review is queued; the pith claim, tier, and objections will appear here once it completes.
SPECIMEN: schema-true, not a live event
T0 review · schema-true
One-sentence machine reading of the paper's core claim.
pith:XXXXXXXX · record.json · timestamp
Signed reviews
read the original abstract
Deep learning-based medical image segmentation faces significant challenges arising from limited labeled data and domain shifts. While prior approaches have primarily addressed these issues independently, their simultaneous occurrence is common in medical imaging. A method that generalizes to unseen domains using only minimal annotations offers significant practical value due to reduced data annotation and development costs. In pursuit of this goal, we propose FSDA-DG, a novel solution to improve cross-domain generalizability of medical image segmentation with few single-source domain annotations. Specifically, our approach introduces semantics-guided semi-supervised data augmentation. This method divides images into global broad regions and semantics-guided local regions, and applies distinct augmentation strategies to enrich data distribution. Within this framework, both labeled and unlabeled data are transformed into extensive domain knowledge while preserving domain-invariant semantic information. Additionally, FSDA-DG employs a multi-decoder U-Net pipeline semi-supervised learning (SSL) network to improve domain-invariant representation learning through consistent prior assumption across multiple perturbations. By integrating data-level and model-level designs, FSDA-DG achieves superior performance compared to state-of-the-art methods in two challenging single domain generalization (SDG) tasks with limited annotations. The code is publicly available at https://github.com/yezanting/FSDA-DG.
Discussion (0). Continue with ORCID to comment.